Comparative Pharmacology
Head-to-head clinical analysis: ANEXSIA versus ANEXSIA 7 5 650.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANEXSIA versus ANEXSIA 7 5 650.
ANEXSIA vs ANEXSIA 7.5/650
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ANEXSIA is a combination of hydrocodone and acetaminophen. Hydrocodone is an opioid agonist that binds to mu-opioid receptors in the central nervous system, altering pain perception and emotional response to pain. Acetaminophen's analgesic mechanism is not fully understood but involves inhibition of COX enzymes in the CNS and modulation of descending serotonergic pathways.
Hydrocodone is a mu-opioid receptor agonist that inhibits ascending pain pathways and alters pain perception; acetaminophen inhibits cyclooxygenase (COX) enzymes, primarily in the CNS, reducing prostaglandin synthesis and fever.
50-100 mg orally every 4-6 hours as needed; maximum 400 mg/day.
1 tablet orally every 4 to 6 hours as needed; maximum 6 tablets per day.
None Documented
None Documented
Terminal elimination half-life is 4-6 hours in adults with normal renal function; prolonged to 12-24 hours in severe renal impairment (CrCl <30 mL/min).
Hydrocodone: Terminal half-life 3.8-7.2 hours (mean 5.6 h). Acetaminophen: 1.5-2.5 hours (therapeutic) but prolonged to >4 hours in overdose with hepatotoxicity risk.
Approximately 70% renal (unchanged drug and metabolites), 20% biliary/fecal, 10% other.
Hydrocodone: Renal elimination of metabolites (hydromorphone, norhydrocodone) and unchanged drug accounts for ~60-90% of clearance. Acetaminophen: ~85% of dose is excreted in urine as glucuronide and sulfate conjugates; 5-10% unchanged; 2-5% as mercapturate.
Category C
Category C
Opioid Analgesic Combination
Opioid Analgesic Combination